In summary, our orally-available bispecific inhibitor TMP1 simultaneously suppresses the activity of SARS-CoV-2 Mpro and host TMPRSS2 with high potency, thus effectively blocking the infections and transmission of human-pathogenic coronaviruses. Here, TMPRSS2 is linked to infection.